The Medicines and Healthcare products Regulatory Agency (MHRA) has launched new functionality to its Yellow Card system for reporting suspected adverse responses, or issues with both pharmaceuticals and medical devices.
The new functionality integrates clinical systems with Yellow Card, allowing for significantly simpler reporting processes. It is hoped this will not only save time, but improve the rate at which suspected adverse effects are reported. In particular, the hope is that the new system will increase reporting rates from secondary care, which have typically lagged behind general practice. The new system has been piloted by Nottinghamshire Healthcare NHS Foundation Trust.